Decision Resources, Inc., announces the publication of Formulary Inclusion and Reimbursement of Anti-Infectives, a new study that outlines strategies to enhance formulary acceptance of current and emerging anti-infectives. Anti-infectives (antibiotics, antivirals, and antifungals) constitute a significant percentage of hospital and managed care organization (MCO) pharmacy budgets; consequently they are a major focus of cost control. Formularies are one of the many control tactics used to promote appropriate and cost-effective use of anti-infective therapies.
Formulary Inclusion and Reimbursement of Anti-Infectives is based on the expert opinions of physicians, pharmacists, and formulary policymakers in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). In the United States-where cost-containment is most aggressive and where the use of formularies as prescribing management tools is most developed-we supplement our study with a survey of 30 hospitals and 30 of the largest MCOs to compare inclusion of selected products and classes of antibiotics.
To triumph in the marketplace, manufacturers must attain formulary inclusion and minimize usage restrictions on their products. The strategies outlined in Formulary Inclusion and Reimbursement of Anti-Infectives will guide pharmaceutical developers in adapting their marketing efforts to the changes occurring in the health care system and navigating future trends in formulary management, including the following:
-- Price competition that will intensify in many mature antibiotic segments (e.g., cephalosporins, fluoroquinolones) as MCOs face tighter cost constraints on their overall pharmaceutical budget following the introduction of costly novel biologics. -- National efforts to limit antibiotic overutilization that may have a negative effect on demand and formulary inclusion in the ambulatory setting. However, products perceived as being active against resistant pathogens will be in great demand. -- The MCO trend toward open, multi-tier formularies in order to shift cost to consumers that will provide some relief from the restrictiveness of closed formularies.
Formulary Inclusion and Reimbursement of Anti-Infectives offers invaluable market intelligence for pharmaceutical companies seeking formulary acceptance of their product. This study is part of the Infectious Disease portfolio, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,